Abstract: The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

Abstract: The present invention provides antibody or the antigen-binding portion thereof bind to carbohydrate antigen, such as Globo series antigens (e.g. Globo H, SSEA-4 or SSEA-3). Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

Abstract: The present disclosure relates to chimeric antigen receptors (CARs), which bind to Globo series antigens (e.g. Globo H, SSEA-3 or SSEA-4), including an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Further, the present methods are also provided for administering CARs to a subject in an amount effective to inhibit cancer cells.

Abstract: A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to stage-specific embryonic antigen 3 (SSEA-3) antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions include an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

Abstract: A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.

Abstract: Antibody drug conjugates (ADC's) comprising a drug moiety/payload conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

Abstract: Provided are methods of identifying inhibitors of ?-secretase that employ modified ?-secretase substrates. The modified ?-secretase substrates have ?-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered ?-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1?-P2? of the ?-secretase cleavage site. Many of the modified ?-secretase substrates are more efficient substrates for ?-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by ?-secretase. Recombinant polynucleotide molecules encoding the modified ?-secretase substrates are provided. Antibodies that recognize cleavage products of the modified ?-secretase substrates are provided. Stable cell lines expressing the modified ?-secretase substrates are provided. Transgenic animals expressing the modified ?-secretase substrates are provided.

Abstract: The present invention provides compounds that are inhibitors of the proteolytic activity of the enzyme ?-secretase, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, processes for making the compounds, and methods of using the compounds to treat Alzheimers disease.

Abstract: Provided are methods of identifying inhibitors of ?-secretase that employ modified ?-secretase substrates. The modified ?-secretase substrates have ?-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered ?-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1?-P2? of the ?-secretase cleavage site. Many of the modified ?-secretase substrates are more efficient substrates for ?-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by ?-secretase. Recombinant polynucleotide molecules encoding the modified ?-secretase substrates are provided. Antibodies that recognize cleavage products of the modified ?-secretase substrates are provided. Stable cell lines expressing the modified ?-secretase substrates are provided. Transgenic animals expressing the modified ?-secretase substrates are provided.

Abstract: Gamma three protease is provided, a novel aspartyl class protease that is capable of taking part in the processing of amyloid precursor protein (APP) to A? peptide. Gamma three protease may be involved in the development and/or progression of Alzheimers disease. Methods of identifying inhibitors of gamma three protease, useful in the prevention or treatment of Alzheimers disease, are disclosed.

Abstract: The present invention provides compounds that are inhibitors of the proteolytic activity of the enzyme ?-secretase, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, processes for making the compounds, and methods of using the compounds to treat Alzheimer s disease.

Abstract: Gamma three protease is provided, a novel aspartyl class protease that is capable of taking part in the processing of amyloid precursor protein (APP) to A? peptide. Gamma three protease may be involved in the development and/or progression of Alzheimers disease. Methods of identifying inhibitors of gamma three protease, useful in the prevention or treatment of Alzheimers disease, are disclosed.

Abstract: The present invention is directed to compounds and pharmaceutical compositions comprising the compounds which are inhibitors of the enzyme gamma secretase and which are useful in the treatment or prevention of diseases in which the beta-amyloid peptide is involved, such as Alzheimer's disease.

Abstract: Provided are methods of identifying inhibitors of &bgr;-secretase that employ modified &bgr;-secretase substrates. The modified &bgr;-secretase substrates have &bgr;-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered &bgr;-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1′-P2′ of the &bgr;-secretase cleavage site. Many of the modified &bgr;-secretase substrates are more efficient substrates for &bgr;-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by &bgr;-secretase. Recombinant polynucleotide molecules encoding the modified &bgr;-secretase substrates are provided. Antibodies that recognize cleavage products of the modified &bgr;-secretase substrates are provided. Stable cell lines expressing the modified &bgr;-secretase substrates are provided.

Abstract: The present invention provides a compound of formula I or a salt thereof: 1